As
filed with the Securities and Exchange Commission on February 24,
2021
Registration
No.
333-
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
S-3
REGISTRATION
STATEMENT
UNDER
THE SECURITIES ACT OF 1933
RAFAEL
HOLDINGS, INC.
(Exact
name of registrant as specified in its charter)
Delaware |
|
26-3199071 |
(State
or other jurisdiction of |
|
(I.R.S.
Employer |
Incorporation
or organization) |
|
Identification
Number) |
520
Broad Street
Newark,
NJ 07102
(212)
658-1450
(Address,
including zip code; telephone number, including area code of
registrant’s principal executive offices)
Howard
Jonas
Chief
Executive Officer
Rafael
Holdings, Inc.
520
Broad Street
Newark,
NJ 07102
(212)
658-1450
(Name,
address, including zip code; telephone number, including area code
of agent for service)
Copies
to:
Dov
T. Schwell, Esq.
Schwell
Wimpfheimer & Associates LLP
37
W. 39th Street, Suite 505
New
York, NY 10018
(646)
328-0795
Approximate
date of commencement of proposed sale to the public: From time
to time after the effective date of this registration statement as
determined by the registrant.
If
the only securities to be offered on this Form are being offered
pursuant to dividend or reinvestment plans, please check the
following box. ☐
If
any of the securities being registered on this Form are to be
offered on a delayed or continuous basis pursuant to Rule 415 under
the Securities Act of 1933, other than securities offered only in
connection with dividend or reinvestment plans, check the following
box. ☒
If
this Form is filed to register additional securities for an
offering pursuant to Rule 462(b) under the Securities Act, please
check the following box and list the Securities Act registration
statement number of the earlier effective registration statement
for the same offering. ☐
If
this Form is a post-effective amendment filed pursuant to Rule
462(c) under the Securities Act, check the following box and list
the Securities Act registration statement number of the earlier
effective registration statement for the same offering.
☐
If
this Form is a registration statement pursuant to General
Instruction I.D. or a post-effective amendment thereto that shall
become effective upon filing with the Commission pursuant to Rule
462(e) under the Securities Act, check the following
box. ☐
If
this Form is a post-effective amendment to a registration statement
filed pursuant to General Instruction I.D. filed to register
additional securities or additional classes of securities pursuant
to Rule 413(b) under the Securities Act, check the following box.
☐
Indicate
by check mark whether the registrant is a large accelerated filer,
an accelerated filer, a non-accelerated filer, or a smaller
reporting company. See the definitions of “large accelerated
filer,” “accelerated filer” and “smaller reporting company” in
Rule 12b-2 of the Exchange Act. (check one):
Large
accelerated filer ☐ |
Accelerated
Filer ☐ |
Non-accelerated
filer ☒ |
Smaller
reporting company ☒ |
Emerging
growth company ☒
If an
emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided
pursuant to Section 7(a)(2)(B) of Securities Act. ☐
CALCULATION
OF REGISTRATION FEE
Title
of Securities to be Registered |
|
Amount
to be Registered(1) |
|
|
Proposed
Maximum
Aggregate
Offering Price |
|
|
Amount
of
Registration Fee(2) |
|
Class
B Common Stock, par value $.01 per share |
|
|
101,844 |
|
|
$ |
4,544,788 |
|
|
$ |
495.84 |
|
(1) |
Consists
of 101,844 shares of the registrant’ s Class B common stock to be
offered and sold by the selling stockholder named herein. Pursuant
to Rule 416 under the Securities Act of 1933, as amended, this
registration statement shall also cover any additional shares of
common stock resulting from stock splits, stock dividends or
similar transactions. |
(2) |
Estimated
solely for purposes of calculating the registration fee in
accordance with Rules 457(c) and 457(h) under the Securities Act of
1933, as amended, based on the average of the high and low reported
sales price on the NYSE on February 23, 2021. |
(3) |
Calculated
pursuant to Rule 457(o) under the Securities Act. $758.25 was previously paid in
connection with the Registrant’s Registration Statement on Form S-3
filed on January 20, 2021 and subsequently withdrawn on February 8,
2021, and is offset against the currently due Registration
Fee. |
The
registrant hereby amends this registration statement on such date
or dates as may be necessary to delay its effective date until the
registrant shall file a further amendment which specifically
states that this registration statement shall thereafter become
effective in accordance with Section 8(a) of the
Securities Act of 1933, as amended, or until the registration
statement shall become effective on such date as the Securities and
Exchange Commission, acting pursuant to said Section 8(a), may
determine.
The information in this prospectus is not complete and may be
changed. We may not sell these securities until the registration
statement filed with the Securities and Exchange Commission is
declared effective. This prospectus is not an offer to sell these
securities and it is not soliciting an offer to buy these
securities in any state where the offer or sale is not
permitted.
SUBJECT TO COMPLETION, DATED February 24, 2021
PROSPECTUS
Rafael
Holdings, Inc.
101,844
Shares
of Class B Common Stock
The
selling stockholder identified in this prospectus may sell,
resell or otherwise dispose of up to 101,844 shares of
our Class B common stock, par value $0.01 per share. We
are not offering any shares of Class B common stock under this
prospectus and will not receive any proceeds from the sale or other
disposition of the shares covered hereby.
The
selling stockholder may, from time to time, sell, resell, transfer
or otherwise dispose of the shares or interests therein on any
stock exchange, market or trading facility on which the shares are
traded or in private transactions at fixed prices, at market prices
prevailing at the time of sale, at prices related to the prevailing
market price, at varying prices determined at the time of sale, or
at negotiated prices. The selling stockholder will
bear all fees, discounts, concessions or commissions, if any, of
broker-dealers or agents in connection with the offering of the
shares by the selling stockholder. See “Plan of
Distribution” beginning on page 8 of this prospectus for
more information about how the selling stockholder may sell his
shares of Class B common stock.
Our
Class B common stock is listed on the NYSE under the symbol “RFL”.
On February 23, 2021, the last reported sale price for our Class B
common stock was $42.79 per share. The applicable prospectus
supplement will contain information, where applicable, as to any
other listing on any securities market or other exchange of the
securities, if any, covered by the prospectus
supplement.
Investing
in our securities involves risks. See “Risk Factors” beginning on
page 3.
Neither
the Securities and Exchange Commission nor any state securities
commission has approved or disapproved of these securities or
determined if this prospectus is truthful or complete. Any
representation to the contrary is a criminal
offense.
The
date of this prospectus is February 24, 2021.
TABLE OF CONTENTS
ABOUT THIS
PROSPECTUS
This
prospectus is a part of a registration statement that we filed with
the Securities and Exchange Commission, or SEC. Under the
registration statement, the selling stockholder may sell, at any
time and from time to time, in one or more offerings, up
to 101,844 shares of Class B common stock.
You should read this prospectus together with the information
incorporated herein by reference as described under the heading
“Where You Can Find Additional Information.”
You
should only rely on the information contained or incorporated by
reference in this prospectus or the registration statement of which
it forms a part. No person has been authorized to give
any information or make any representations other than those
contained or incorporated by reference in this prospectus in
connection with the offering described herein and therein, and, if
given or made, such information or representations must not be
relied upon as having been authorized by us or the selling
stockholder.
You
should read the entire prospectus, as well as the documents
incorporated by reference into this prospectus before making an
investment decision. Neither the delivery of this
prospectus nor any sale made hereunder shall under any
circumstances imply that the information contained or incorporated
by reference herein is correct as of any date subsequent to the
date hereof. You should assume that the information
appearing in this prospectus or any document incorporated by
reference is accurate only as of the date of the applicable
documents, regardless of the time of delivery of this prospectus or
any sale of securities. Our business, financial
condition, results of operations and prospects may have changed
since that date.
This
prospectus does not constitute an offer to sell or the solicitation
of an offer to buy any securities other than the registered
securities to which they relate, nor does this prospectus
constitute an offer to sell or the solicitation of an offer to buy
securities in any jurisdiction to any person to whom it is unlawful
to make such offer or solicitation in such jurisdiction.
As
used in this prospectus, “Rafael Holdings, Inc.,” “Rafael,” “the
Company,” “we,” “our,” “ours,” and “us” refer to Rafael Holdings,
Inc. and its consolidated subsidiaries.
SUMMARY
This
summary highlights selected information from this prospectus and
the documents incorporated herein by reference and does not contain
all of the information that you need to consider in making your
investment decision. You should carefully read the entire
prospectus, including the risks of investing in our securities
discussed under “Risk Factors” beginning on page 3 of this
prospectus, the information incorporated herein by reference,
including our financial statements, and the exhibits to the
registration statement of which this prospectus is a part. All
references in this prospectus to “we,” “us,” “our,” “Rafael,”
“Rafael Holdings, Inc.”, the “Company” and similar designations
refer to Rafael Holdings, Inc. and its consolidated subsidiaries,
unless otherwise indicated or as the context otherwise
requires.
Our
Business
Rafael
Holdings, Inc. (“Rafael Holdings” or the “Company”), a Delaware
corporation, owns interests in pre-clinical and clinical stage
pharmaceutical companies and commercial real estate assets. The
assets are operated as two separate lines of business.
The
pharmaceutical holdings include preferred and common equity
interests and a warrant to purchase additional equity interests in
Rafael Pharmaceuticals, Inc., or Rafael Pharmaceuticals, which is a
clinical stage, oncology-focused pharmaceutical company committed
to the development and commercialization of therapies that exploit
the metabolic differences between normal cells and cancer cells;
and, a majority equity interest in LipoMedix Pharmaceuticals Ltd.,
or LipoMedix, a clinical stage oncological pharmaceutical company
based in Israel. In addition, in 2019, we established the Barer
Institute (“Barer”), a wholly-owned early stage venture focused on
developing a pipeline of therapeutic compounds, including compounds
to regulate cancer metabolism. The venture is pursuing
collaborative research agreements with leading scientists from top
academic institutions to develop other early stage ventures such as
the launching of a joint venture which has entered into an
agreement with Princeton University's Office of
Technology Licensing for technology for an exclusive worldwide
license to its SHMT (serine hydroxymethyltransferase) inhibitor
program. In addition, we have recently initiated efforts to develop
other early stage pharmaceutical ventures.
The
commercial real estate holdings consist of a building at 520 Broad
Street in Newark, New Jersey that serves as headquarters for the
Company and certain other related entities and hosts other tenants
and an associated 800-car public garage, and a portion of a
building in Israel. On August 28, 2020 we sold a 3-story, 65,253
square foot office building located at 225 Old New Brunswick Road
in Piscataway, New Jersey for $3,875,000.
Rafael
Pharmaceuticals recently announced two milestones in its clinical
trial phase programs including completing target enrollment of 500
patients of its pivotal phase 3 pancreatic cancer program, ahead of
schedule in August 2020, and in October 2020 crossing enrollment of
its hundredth patient in its pivotal phase 3 study for relapsed or
refractory Acute Myeloid Leukemia (“AML”). Additionally, the U.S.
Food and Drug Administration (“FDA”) has granted Fast Track
designation for Rafael Pharmaceuticals’ lead compound, CPI-613®
(devimistat), for the treatment of both metastatic pancreatic
cancer and AML.
Risks
and Uncertainties - COVID-19
In
December 2019, a new coronavirus, now known as COVID-19, which has
proved to be highly contagious, emerged in Wuhan, China and has
since spread around the globe. The Company actively monitors the
outbreak and its potential impact on its operations and those of
the Company’s holdings. Although the Company’s operations are
mainly in the United States, the Company has assets outside of the
United States, and some of the Company’s pharmaceutical holdings
conduct operations, manufacturing and clinical trial activities in
Europe and Asia.
The
impacts on the operations and specifically the ongoing clinical
trials of our pharmaceutical holdings have been actively managed by
respective pharmaceutical management teams who have worked closely
with the appropriate regulatory agencies to continue clinical trial
activities with as minimal impact as possible including receiving
waivers for certain clinical trial activities from the respective
regulatory agencies to continue the studies.
The
Company had one tenant that did not pay rent in August 2020 due to
the New Jersey state gym closures; however, the tenant subsequently
resumed rent payments for September and onward. There is a general
degree of uncertainty in the national commercial real estate market
based on the COVID-19 pandemic and as a result there is a potential
impact to the value of the Company’s real estate portfolio as well
as efforts to monetize those assets.
The
Company has implemented a number of measures to protect the health
and safety of our workforce including a mandatory work-from-home
policy for our workforce who can perform their jobs from home as
well as restrictions on business travel and workplace and in-person
meetings.
Due
to both known and unknown risks, including quarantines, closures
and other restrictions resulting from the outbreak, operations and
those of the Company’s holdings may be adversely impacted.
Additionally, as there is an evolving nature to the COVID-19
situation, we cannot reasonably assess or predict at this time the
full extent of the negative impact that the COVID-19 pandemic may
have on our business, financial condition, results of operations
and cash flows. The impact will depend on future developments such
as the ultimate duration and the severity of the spread of the
COVID-19 pandemic in the U.S. and globally, the effectiveness of
federal, state, local and foreign government actions on mitigation
and spread of COVID-19, the pandemic’s impact on the U.S. and
global economies, changes in our customers’ behavior emanating from
the pandemic and how quickly we can resume our normal operations,
among others. For all these reasons, the Company may incur expenses
or delays relating to such events outside of the Company’s control,
which could have a material adverse impact on the Company’s
business.
Recent
Financing
On
December 7, 2020, we entered into a Securities Purchase Agreement
(the “SPA”) for the sale of 567,437 shares of our Class B common
stock at a price per share of $22.91 (which was the closing price
for the Class B common stock on the New York Stock Exchange on
December 4, 2020 the trading day immediately preceding the date of
the SPA) for an aggregate purchase price of $13 million. In
connection with the SPA, each purchaser was granted warrants to
purchase twenty percent (20%) of the shares of Class B common stock
purchased by such purchaser. The warrants have an exercise price of
$22.91 per share and expire on June 6, 2022. We issued warrants to
purchase an aggregate of 113,487 shares of Class B common
stock.
On
January 22, 2021, Pharma Holdings, LLC (the “Subsidiary”), our
90%-owned subsidiary, used a majority of the proceeds received
pursuant to the SPA to partially exercise a warrant (the “Warrant”)
to purchase Series D Convertible Preferred Stock of Rafael
Pharmaceuticals, Inc. (“Rafael Pharmaceuticals”). The Subsidiary
purchased 7,298,950 shares of Rafael Pharmaceuticals’ Series D
Convertible Preferred Stock for $9,123,687. The Warrant is
exercisable for up to 56.0% of the equity of Rafael
Pharmaceuticals. Commensurate with its interest in the Subsidiary,
the Company funded 90% of the aggregate exercise price. Following
the exercise, we and our subsidiaries collectively own securities
representing 51.0% of the outstanding capital stock of Rafael
Pharmaceuticals and 41.1% of the capital stock on a fully diluted
basis (excluding the remainder of the Warrant). The exercise
allowed us to maintain its ownership of majority of the outstanding
capital stock of Rafael Pharmaceuticals (and to increase our
position in Rafael Pharmaceuticals on a fully diluted basis
(excluding the remainder of the Warrant)) in light of issuances of
Rafael Pharmaceuticals equity securities to third parties
stockholders, including due to warrant exercises by these
stockholders.
We
intend to use additional proceeds received pursuant to the SPA to
fund the operations of our drug development programs including
through the Barer Institute, and for general corporate purposes.
Under the SPA, two entities, on whose Boards of Directors Howard
Jonas, our Chief Executive Officer and Chairman of the Board
serves, each purchased 218,245 shares of Class B common stock for
consideration of $10 million.
The
Offering
The
selling stockholder named in this prospectus may offer and sell up
to 101,844 shares of our Class B common stock, par value
$0.01 per share. Our Class B common stock is currently listed
on The New York Stock Exchange under the symbol “RFL.” Shares
of our Class B common stock that may be offered under this
prospectus will be fully paid and non-assessable. We will not
receive any of the proceeds of sales by the selling stockholder of
any of the Class B common stock covered by this prospectus.
Throughout this prospectus, when we refer to the shares of our
Class B common stock being registered on behalf of the selling
stockholder for offer and sale, we are referring to
the shares that are being registered for resale by
the selling stockholder pursuant to the terms of
the Membership Interest Purchase Agreement by and between us
and Robert Rodriguez, dated December 7, 2020, whereby we purchased
the economic rights to Mr. Rodriguez’s thirty-three and one-third
percent (33.33%) interest in Altira Capital & Consulting, LLC
(the “Purchase Agreement”). Under the Purchase Agreement, we may
pay up to $6,950,000 of the purchase price in shares of Class B
common stock and have the obligation to register the resale of such
shares. When we refer to the selling stockholder in this
prospectus, we are referring to the holder of registration
rights under the Purchase Agreement. See “Selling
Stockholder” beginning on page 7 of this
prospectus.
Class
B Common Stock
The
selling shareholder may offer to sell shares of our Class B common
stock, par value $0.01 per share. Holders of our Class B common
stock are entitled to receive dividends as our board of directors
may declare from time to time out of legally available funds,
subject to the preferential rights of the holders of any shares of
our preferred stock that are outstanding or that we may issue in
the future. Currently, we do not have any issued and outstanding
preferred stock. Each holder of our Class B common stock is
entitled to one tenth of one vote per share. In this prospectus, we
provide a general description of, among other things, our dividend
policy and the rights and restrictions that apply to holders of our
Class B common stock. Our Class B common stock is described in
greater detail in this prospectus under “Description of Capital
Stock — Class B Common Stock.”
RISK
FACTORS
Investment
in our securities involves risks. Prior to making a decision about
investing in our securities, you should consider carefully all of
the information included and incorporated by reference or deemed to
be incorporated by reference in this prospectus or the applicable
prospectus supplement, including the risk factors incorporated by
reference herein from our Form 10-K for the fiscal year ended July
31, 2020, as updated by annual, quarterly and other reports and
documents we file with the Securities and Exchange Commission (the
“SEC”) since July 31, 2020, including after the date of this
prospectus and that are incorporated by reference herein or in the
applicable prospectus supplement. Each of these risk factors could
have a material adverse effect on our business, results of
operations, financial position or cash flows, which may result in
the loss of all or part of your investment.
FORWARD-LOOKING
STATEMENTS
This
prospectus and the documents incorporated herein by reference
contain forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. These statements
are based on our management’s current beliefs, expectations and
assumptions about future events, conditions and results and on
information currently available to us. Discussions containing these
forward-looking statements may be found, among other places, in the
Sections entitled “Business,” “Risk Factors” and “Management’s
Discussion and Analysis of Financial Condition and Results of
Operations” incorporated by reference from our most recent Annual
Report on Form 10-K and in our Quarterly Reports on Form 10-Q, as
well as any amendments thereto, filed with the SEC.
All
statements, other than statements of historical fact, included or
incorporated herein regarding our strategy, future operations,
financial position, future revenues, projected costs, plans,
prospects and objectives are forward-looking statements. Words such
as “expect,” “anticipate,” “intend,” “plan,” “believe,” “seek,”
“estimate,” “think,” “may,” “could,” “will,” “would,” “should,”
“continue,” “potential,” “likely,” “opportunity” and similar
expressions or variations of such words are intended to identify
forward-looking statements, but are not the exclusive means of
identifying forward-looking statements. Additionally, statements
concerning future matters such as our expectations of business and
market conditions, development and commercialization of new
products, enhancements of existing products or technologies, and
other statements regarding matters that are not historical are
forward-looking statements. Such statements are based on currently
available operating, financial and competitive information and are
subject to various risks, uncertainties and assumptions that could
cause actual results to differ materially from those anticipated or
implied in our forward-looking statements due to a number of
factors including, but not limited to, those set forth above under
the section entitled “Risk Factors” in this prospectus and any
accompanying prospectus supplement. Given these risks,
uncertainties and other factors, many of which are beyond our
control, you should not place undue reliance on these
forward-looking statements.
Except
as required by law, we assume no obligation to update these
forward-looking statements publicly, or to revise any
forward-looking statements to reflect events or developments
occurring after the date of this prospectus, even if new
information becomes available in the future.
USE OF
PROCEEDS
We
are registering these shares pursuant to registration rights
granted to the selling stockholder. We are not selling any
securities under this prospectus and we will not receive any
of the proceeds from the sale or other disposition by the selling
stockholder of the shares of Class B common stock covered
hereby.
We
have agreed to pay all costs, expenses and fees relating to
registering the shares of our Class B common stock referenced in
this prospectus. The selling stockholder will pay any brokerage
commissions and/or similar charges incurred in connection with the
sale or other disposition by him of the shares covered
hereby.
See
“Selling Stockholder” and “Plan of Distribution” described
below.
DESCRIPTION OF OUR
CAPITAL STOCK
Our
authorized capital stock consists of (i) 35 million shares of Class
A common stock, (ii) 200 million shares of Class B common stock,
and (iii) 10 million shares of Preferred Stock.
Class
A Common Stock
Holders
of shares of our Class A common stock are entitled to three votes
for each share on all matters to be voted on by the stockholders.
Holders of our Class A common stock are entitled to share ratably
in dividends, if any, as may be declared from time to time by the
Board of Directors in its discretion from funds legally available
therefor. Each share of our Class A common stock may be converted,
at any time and at the option of the holder, and automatically
converts upon transfers to unaffiliated parties, into one fully
paid and non-assessable share of our Class B common
stock.
As of
February 23, 2021, there were 787,163 of our shares of Class A
common stock outstanding.
Class
B Common Stock
Holders
of shares of our Class B common stock are entitled to one tenth of
one vote for each share on all matters to be voted on by the
stockholders. Holders of our Class B common stock are entitled to
share ratably in dividends, if any, as may be declared from time to
time by the Board of Directors in its discretion from funds legally
available therefor.
As of
February 23, 2021, there were 15,884,473 shares of Class B common
stock outstanding.
Preferred
Stock
The
Board of Directors has the authority to fix the price, rights,
preferences, privileges and restrictions, including voting rights,
of those shares without any further vote or action by the
stockholders.
As of
February 23, 2021, there were no shares of our preferred stock
outstanding.
Anti-Takeover
Effects of Our Charter and By-Laws
Some
provisions of Delaware law and our Certificate of Incorporation and
By-Laws could make the following more difficult:
|
● |
acquisition
of us by means of a tender offer; |
|
● |
acquisition
of us by means of a proxy contest or otherwise; or |
|
● |
removal
of our incumbent officers and directors. |
These
provisions, summarized below, are expected to discourage coercive
takeover practices and inadequate takeover bids. These provisions
also are designed to encourage persons seeking to acquire control
of us to first negotiate with our Board of Directors. We believe
that the benefits of increased protection give us the potential
ability to negotiate with the proponent of an unfriendly or
unsolicited proposal to acquire or restructure us and outweigh the
disadvantages of discouraging those proposals because negotiation
of them could result in an improvement of their terms.
Certificate of Incorporation; By-Laws
Our
Certificate of Incorporation and By-Laws contain provisions that
could make more difficult the acquisition of us by means of a
tender offer, a proxy contest or otherwise. These provisions are
summarized below.
Undesignated
Preferred Stock. The authorization of our undesignated
preferred stock makes it possible for our Board of Directors to
issue our preferred stock with voting or other rights or
preferences that could impede the success of any attempt to change
control of us. These and other provisions may have the effect of
deferring hostile takeovers or delaying changes of control of our
management.
Size
of Board and Vacancies. Our Certificate of Incorporation
provides that the number of directors on our Board of Directors
will be between two and seventeen. Newly created directorships
resulting from any increase in our authorized number of directors
or any vacancies in our Board of Directors resulting from death,
resignation, retirement, disqualification, removal from office or
other cause will be filled solely by the vote of our remaining
directors in office.
Disparate
Voting Rights. Holders of shares of our Class A common stock
are entitled to three votes for each share and holders of shares of
Class B common stock are entitled to one tenth of one vote for each
share on all matters to be voted on by the stockholders.
NYSE
Listing
Our
Class B common stock is listed on the NYSE and trades under the
symbol “RFL.”
Transfer
Agent and Registrar
The
transfer agent and registrar for our capital stock is American
Stock Transfer & Trust, LLC.
SELLING
STOCKHOLDER
Pursuant
to the Purchase Agreement, we agreed to file the registration
statement of which this prospectus forms a part to cover
the resale of 101,844 shares of our Class B common stock
issued to the selling stockholder in accordance with the Purchase
Agreement, and to keep such registration statement effective
until all the shares issued pursuant to the Purchase Agreement have
been sold pursuant to such registration statement or may sold
without restriction under Rule 144(b)(i) of the Securities
Act.
Registration of Shares under the Purchase
Agreement
We
are registering the shares in accordance with the terms of the
Purchase Agreement to permit the selling stockholder, to sell,
resell or otherwise dispose of the shares in a manner contemplated
under “Plan of Distribution” in this prospectus. Throughout this
prospectus, when we refer to the selling stockholder in this
prospectus we are referring to the holder of registration rights
under the Purchase Agreement.
The
selling stockholder may sell some, all or none of the shares he
owns that are covered by the registration statement. We do not know
how long the selling stockholder will hold the shares before
selling them, and we currently have no agreements, arrangements or
understandings with the selling stockholder regarding the sale or
other disposition of any of the shares. The shares covered hereby
may be offered from time to time by the selling
stockholder.
The
following table sets forth the name of the selling stockholder, the
number and percentage of our Class B common stock beneficially
owned by the selling stockholder as of February 23, 2021, the
number of shares that may be offered under this prospectus, and the
number and percentage of our Class B common stock beneficially
owned by the selling stockholder assuming all of the shares covered
hereby are sold. Beneficial ownership is determined in accordance
with the rules of the SEC and includes voting or investment power
with respect to our Class B common stock.
All
information contained in the table below is based upon information
provided to us by the selling stockholder. The percentage of our
shares owned after the offering is based on 15,884,473 shares of
Class B common stock outstanding as of February 23, 2021. Unless
otherwise indicated in the footnotes to this table, we believe that
the selling stockholder named in this table has sole voting power
with respect to the shares of Class B common stock indicated as
beneficially owned.
The
address of the stockholder listed on the table is c/o Rafael
Holdings, Inc., 520 Broad Street, Newark, New Jersey
07102.
|
|
Number of Shares Beneficially Owned Prior to this Offering |
|
|
Number of Shares Being Sold |
|
|
Number of Shares Beneficially Owned After this Offering |
|
Selling Stockholder |
|
Number |
|
|
Percent |
|
|
Offered |
|
|
Number |
|
|
Percent |
|
Robert
Rodriguez |
|
|
101,844 |
|
|
|
* |
|
|
|
101,844 |
|
|
|
0 |
|
|
|
* |
|
PLAN OF
DISTRIBUTION
We
are registering the shares of Class B common stock issued to the
selling stockholder to permit the sale and resale of
these shares of Class B common stock by the selling stockholder
from time to time from after the date of this
prospectus.
The
selling stockholder may, from time to time, sell any or all of his
shares of Class B common stock covered hereby on the New York Stock
Exchange or any other stock exchange, market or trading facility on
which the shares are traded or in private
transactions. These sales may be at fixed prices, at
prevailing market prices at the time of the sale, at varying prices
determined at the time of sale, or privately negotiated
prices. The selling stockholder may use any one or more
of the following methods when selling shares:
|
● |
ordinary
brokerage transactions and transactions in which the broker-dealer
solicits purchasers; |
|
|
|
|
● |
block
trades in which the broker-dealer will attempt to sell the shares
as agent but may position and resell a portion of the block as
principal to facilitate the transaction; |
|
|
|
|
● |
purchases
by a broker-dealer as principal and resale by the broker-dealer for
its account; |
|
|
|
|
● |
an
exchange distribution in accordance with the rules of the
applicable exchange; |
|
|
|
|
● |
privately
negotiated transactions; |
|
|
|
|
● |
settlement
of short sales, to the extent permitted by law; |
|
|
|
|
● |
in
transactions through broker-dealers that agree with the selling
stockholder to sell a specified number of such shares at a
stipulated price per share; |
|
|
|
|
● |
through
the writing or settlement of options or other hedging transactions,
whether through an options exchange or otherwise; |
|
|
|
|
● |
a
combination of any such methods of sale; or |
|
|
|
|
● |
any
other method permitted pursuant to applicable law. |
The
selling stockholder may also sell the shares of Class B common
stock under Rule 144 under the Securities Act, if available,
rather than under this prospectus.
Broker-dealers
engaged by the selling stockholder may arrange for other
brokers-dealers to participate in sales. Broker-dealers may receive
commissions or discounts from the selling stockholder (or, if any
broker-dealer acts as agent for the purchaser of shares, from the
purchaser) in amounts to be negotiated, but, except as set forth in
a supplement to this prospectus, in the case of an agency
transaction not in excess of a customary brokerage commission in
compliance with FINRA Rule 2121; and in the case of a principal
transaction a markup or markdown in compliance with FINRA Rule
2121.
The
aggregate proceeds to the selling stockholder from the sale of the
Class B common stock offered by him will be the purchase
price of the common stock less discounts or commissions, if any.
The selling stockholder reserves the right to accept and,
together with their agents from time to time, to reject, in
whole or in part, any proposed purchase of Class B common stock to
be made directly or through agents. We will not receive any of
the proceeds from the sale by the selling stockholder of the shares
of Class B common stock.
In
connection with the sale of the shares of Class B common stock or
interests therein, the selling stockholder may enter into hedging
transactions with broker-dealers or other financial institutions,
which may in turn engage in short sales of the shares of Class B
common stock in the course of hedging the positions they assume.
The selling stockholder may also sell the shares of Class B common
stock short and deliver these securities to close out their short
positions or to return borrowed shares in connection with such
short sales, or loan or pledge the shares of Class B common stock
to broker-dealers that in turn may sell these securities. The
selling stockholder may also enter into option or other
transactions with broker-dealers or other financial institutions or
create one or more derivative securities which require the delivery
to such broker-dealer or other financial institution of shares of
Class B common stock offered by this prospectus, which shares such
broker-dealer or other financial institution may resell pursuant to
this prospectus (as supplemented or amended to reflect such
transaction).
The
selling stockholder and any broker-dealers or agents that are
involved in selling the shares of Class B common stock may be
deemed to be “underwriters” within the meaning of the Securities
Act in connection with such sales. In such event, any commissions
received by the selling stockholder, broker-dealers or agents and
any profit on the resale of the shares purchased by them may be
deemed to be underwriting commissions or discounts under the
Securities Act.
In
the event, the selling stockholder is an “underwriter” within the
meaning of Section 2(11) of the Securities Act will be subject to
the prospectus delivery requirements of the Securities Act and may
be subject to certain statutory liabilities of, including but not
limited to, Sections 11, 12 and 17 of the Securities Act and Rule
10b-5 under the Exchange Act. The selling stockholder has informed
us that it is not a registered broker-dealer or an affiliate of a
registered broker-dealer. In no event shall any broker-dealer
receive fees, commissions and markups which, in the aggregate,
would exceed eight percent (8%).
We
are required to pay certain fees and expenses incurred by us
incident to the registration of the shares. We have agreed to
indemnify the selling stockholder against certain losses, claims,
damages and liabilities, including liabilities under the Securities
Act, and the selling stockholder may be entitled to contribution.
We may be indemnified by the selling stockholder against certain
losses, claims, damages and liabilities, including liabilities
under the Securities Act that may arise from any written
information furnished to us by the selling stockholder specifically
for use in this prospectus, or we may be entitled to
contribution.
We
agreed to cause the registration statement of which this prospectus
is a part to remain effective for the period set forth in
the Purchase Agreement. Shares of Class B common stock will
be sold only through registered or licensed brokers or dealers if
required under applicable state securities laws. In addition, in
certain states, the shares of Class B common stock covered hereby
may not be sold unless they have been registered or qualified for
sale in the applicable state or an exemption from the registration
or qualification requirement is available and complied
with.
Under
applicable rules and regulations under the Exchange Act, any person
engaged in the distribution of the shares of Class B common stock
may not simultaneously engage in market making activities with
respect to the shares of Class B common stock for the applicable
restricted period, as defined in Regulation M, prior to the
commencement of the distribution. In addition, the selling
stockholder will be subject to applicable provisions of the
Exchange Act and the rules and regulations thereunder, including
Regulation M, which may limit the timing of purchases and sales of
shares of Class B common stock by the selling stockholder or any
other person. We will make copies of this prospectus available to
the selling stockholder and have informed him of the need to
deliver a copy of this prospectus at or prior to the time of the
sale (including by compliance with Rule 172 under the Securities
Act).
To
the extent required, the shares of our Class B common stock to be
sold, the name of the selling stockholder, the respective
purchase prices and public offering prices, the names of any
agents, dealer or underwriter, any applicable commissions or
discounts with respect to a particular offer will be set forth
in an accompanying prospectus supplement or, if appropriate, a
post-effective amendment to the registration statement that
includes this prospectus.
There
can be no assurance that the selling stockholder will sell any or
all of the shares of Class B common stock we registered on behalf
of the selling stockholder pursuant to the registration statement
of which this prospectus forms a part.
Once
sold under the registration statement of which this prospectus
forms a part, the shares of Class B common stock will be freely
tradable in the hands of persons other than our
affiliates.
LEGAL
MATTERS
Schwell
Wimpfheimer & Associates, LLP, New York, New York, will pass
for us upon the validity of the securities being offered by this
prospectus and applicable prospectus supplement, and counsel named
in the applicable prospectus supplement will pass upon legal
matters for any underwriters, dealers or agents. Certain partners
of the Firm are the beneficial owner of an aggregate of 9,249
shares of Class B Common Stock, consisting of (a) 2,499 unvested
restricted shares Class B Common Stock, and (b) 6,750 shares of
Class B Common Stock.
EXPERTS
The
consolidated financial statements of Rafael Holdings, Inc.
appearing in Rafael Holdings, Inc.’s Annual Report on Form 10-K for
the year ended July 31, 2020, have been audited by CohnReznick LLP,
independent registered public accounting firm, as set forth in
their report thereon, included therein, and incorporated herein by
reference. Such consolidated financial statements are incorporated
herein by reference in reliance upon such report given on the
authority of such firm as experts in accounting and
auditing.
WHERE YOU CAN FIND
ADDITIONAL INFORMATION
We
are a reporting company and file annual, quarterly and current
reports, proxy statements and other information with the SEC. We
have filed with the SEC a registration statement on Form S-3 under
the Securities Act with respect to the securities we are offering
under this prospectus. This prospectus does not contain all of the
information set forth in the registration statement and the
exhibits to the registration statement. For further information
with respect to us and the securities we are offering under this
prospectus, we refer you to the registration statement and the
exhibits and schedules filed as a part of the registration
statement. The SEC maintains an internet site that contains
reports, proxy and information statements, and other information
regarding issuers that file electronically with the SEC, where our
SEC filings are also available. The address of the SEC’s web site
is http://www.sec.gov. We maintain a website at
http://www.rafaelholdings.com. Information contained in or
accessible through our website does not constitute a part of this
prospectus.
INCORPORATION
OF CERTAIN INFORMATION BY REFERENCE
The
SEC allows us to “incorporate by reference” information that we
file with it into this prospectus, which means that we can disclose
important information to you by referring you to those documents.
The information incorporated by reference is an important part of
this prospectus. Information in this prospectus supersedes
information incorporated by reference that we filed with the SEC
prior to the date of this prospectus, while information that we
file later with the SEC will automatically update and supersede the
information in this prospectus. We incorporate by reference into
this registration statement and prospectus the following documents,
and any future filings we will make with the SEC under Sections
13(a), 13(c), 14 or 15(d) of the Exchange Act after the date of the
initial registration statement but prior to effectiveness of the
registration statement and after the date of this prospectus but
prior to the termination of the offering of the securities covered
by this prospectus (other than current reports or portions thereof
furnished under Item 2.02 or Item 7.01 of Form
8-K):
|
● |
Our Annual
Report on
Form 10-K for the year ended July 31, 2020, filed with the SEC
on October 29, 2020;
|
|
● |
Our Quarterly Report on
Form 10-Q for the year quarter ended October 31, 2020, filed
with the SEC on December 15, 2020;
|
|
● |
Our Current
Reports on Form 8-K filed with the SEC on
September 1, 2020,
October 29, 2020,
December 11, 2020,
December 15, 2020,
January 19, 2021 and
January 28, 2021;
|
|
● |
Our
definitive proxy statement on
Schedule 14A filed with the SEC on November 23, 2020;
and |
|
● |
Description
of our Class B common stock set forth under Item 11 in
Post-Effective Amendment No. 3 to the Registrant’s Registration
Statement on
Form 10, filed with the SEC on March 26, 2018, and
contained in Exhibit 4.2 to our Annual Report on 10-K filed
with SEC on October 29, 2020, including any amendment or report
filed for the purpose of updating such information.
|
We
will provide each person, including any beneficial owner, to whom a
prospectus is delivered, a copy of any or all of the information
that has been incorporated by reference into this prospectus but
not delivered with this prospectus upon written or oral request at
no cost to the requester. Requests should be directed to: Rafael
Holdings, Inc., 520 Broad Street, Newark, New Jersey 07102, Attn:
Investor Relations, or you may call us at (212)
658-1450.
RAFAEL
HOLDINGS, INC.
101,844
Shares
of Class B Common Stock
PROSPECTUS
February
24, 2021
PART II
INFORMATION
NOT REQUIRED IN PROSPECTUS
14.
Other Expenses of Issuance and Distribution
The
following statement sets forth the estimated expenses in connection
with the offering described in the registration statement (all of
which will be borne by Rafael Holdings, Inc.).
Securities
and Exchange Commission Fee |
|
$ |
495.84 |
|
Accountants’
Fees and Expenses |
|
$ |
7,500 |
|
Legal
Fees and Expenses |
|
$ |
4,000 |
|
Printing
Fees |
|
$ |
484
|
|
Miscellaneous |
|
$ |
- |
|
TOTAL |
|
$ |
12,479.84
|
|
15.
Indemnification of Officers and Directors
Delaware
law authorizes corporations to eliminate the personal liability of
directors to corporations and their stockholders for monetary
damages for breach or alleged breach of the directors' "duty of
care". While the relevant statute does not change directors' duty
of care, it enables corporations to limit available relief to
equitable remedies such as injunction or rescission. The statute
has no effect on directors' duty of loyalty, acts or omissions not
in good faith or involving intentional misconduct or knowing
violations of law, illegal payment of dividends and approval of any
transaction from which a director derives an improper personal
benefit.
The
Company has adopted provisions in its Amended and Restated
Certificate of Incorporation, as amended, which eliminate the
personal liability of its directors to the Company and its
stockholders for monetary damages for breach or alleged breach of
their duty of care. The bylaws of the Company provide for
indemnification of its directors, officers, employees and agents to
the fullest extent permitted by the General Corporation Law of the
State of Delaware, the Company's state of incorporation, including
those circumstances in which indemnification would otherwise be
discretionary under Delaware Law. Section 145 of the General
Corporation Law of the State of Delaware permits a corporation to
indemnify any director or officer of the corporation against
expenses (including attorneys’ fees), judgments, fines, and amounts
paid in settlement actually and reasonably incurred in connection
with any action, suit, or proceeding brought by reason of the fact
that such person is or was a director or officer of the
corporation, if such person acted in good faith and in a manner
that he or she reasonably believed to be in, or not opposed to, the
best interests of the corporation, and, with respect to any
criminal action or proceeding, if he or she had no reason to
believe his or her conduct was unlawful. In a derivative action, or
an action brought by or on behalf of the corporation,
indemnification may be provided only for expenses actually and
reasonably incurred by any director or officer in connection with
the defense or settlement of such an action or suit if such person
acted in good faith and in a manner that he or she reasonably
believed to be in, or not opposed to, the best interests of the
corporation, except that no indemnification shall be provided if
such person shall have been adjudged to be liable to the
corporation, unless and only to the extent that the court in which
the action or suit was brought shall determine that the defendant
is fairly and reasonably entitled to indemnity for such expenses
despite such adjudication of liability.
The
Company may enter into indemnification agreements with certain of
its executive officers and directors, indemnifying them against
certain potential liabilities that may arise as a result of their
service to the Company, and providing certain other protections.
The Company also maintains insurance policies which insure the
officers and directors against certain liabilities.
16.
Exhibits
EXHIBIT
LIST
|
(1) |
Incorporated
by reference to Form 10-12G/A, filed March 26, 2018. |
|
(2) |
Incorporated
by reference to Form 8-K, filed September 26, 2019. |
17.
Undertakings
The
undersigned registrant hereby undertakes:
1) To
file, during any period in which offers or sales are being made, a
post-effective amendment to this registration statement:
(i) to include any prospectus required by
Section 10(a)(3) of the Securities Act; (ii) to
reflect in the prospectus any facts or events arising after the
effective date of the registration statement (or the most recent
post-effective amendment thereof) which, individually or in the
aggregate, represent a fundamental change in the information set
forth in the registration statement. Notwithstanding the
foregoing, any increase or decrease in volume of securities offered
(if the total dollar value of securities offered would not exceed
that which was registered) and any deviation from the low or high
end of the estimated maximum offering range may be reflected in the
form of prospectus filed with the Securities and Exchange
Commission (the “Commission”), pursuant to
Rule 424(b) if, in the aggregate, the changes in volume
and price represent no more than 20 percent change in the maximum
aggregate offering price set forth in the “Calculation of
Registration Fee” table in the effective registration statement;
and (iii) to include any material information with respect to
the plan of distribution not previously disclosed in the
registration statement or any material change to such information
in the registration statement;
Provided,
however, that paragraphs (a)(1)(i), (a)(1)(ii) and
(a)(1)(iii) do not apply if the registration statement is on
Form S-3 or Form F-3 and the information required to be included in
a post-effective amendment by those paragraphs is contained in
reports filed with or furnished to the Commission by the registrant
pursuant to Section 13 or Section 15(d) of the
Securities Exchange Act of 1934 (the “Exchange Act”), that are
incorporated by reference in the registration statement, or is
contained in a form of prospectus filed pursuant to
Rule 424(b) that is part of the registration
statement.
2)
That, for the purpose of determining any liability under the
Securities Act, each such post-effective amendment shall be deemed
to be a new registration statement relating to the securities
offered therein, and the offering of such securities at that time
shall be deemed to be the initial bona
fide offering thereof.
3) To
remove from registration by means of a post-effective amendment any
of the securities being registered which remain unsold at the
termination of the offering.
4)
That, for the purpose of determining liability under the Securities
Act to any purchaser:
i.
Each prospectus filed by the registrant pursuant to
Rule 424(b)(3) shall be deemed to be part of the
registration statement as of the date the filed prospectus was
deemed part of and included in the registration statement;
and
ii.
Each prospectus required to be filed pursuant to
Rule 424(b)(2), (b)(5) or (b)(7) as part of a
registration statement in reliance on Rule 430B relating to an
offering made pursuant to Rule 415(a)(1)(i), (vii) or
(x) for the purpose of providing the information required by
Section 10(a) of the Securities Act shall be deemed to be
part of and included in the registration statement as of the
earlier of the date such form of prospectus is first used after
effectiveness or the date of the first contract of sale of
securities in the offering described in prospectus. As
provided in Rule 430B, for liability purposes of the issuer
and any person that is at that date an underwriter, such date shall
be deemed to be a new effective date of the registration statement
relating to the securities in the registration statement to which
the prospectus relates, and the offering of such securities at that
time shall be deemed to be the initial bona fide offering
thereof. Provided, however , that no
statement made in a registration statement or prospectus that is
part of the registration statement or made in a document
incorporated or deemed incorporated by reference into the
registration statement or prospectus that is part of the
registration statement will, as to a purchaser with a time of
contract of sale prior to such effective date, supersede or modify
any statement that was made in the registration statement or
prospectus that was part of the registration statement or made in
any such document immediately prior to such effective date;
or
iii.
If the registrant is subject to Rule 430C, each prospectus filed
pursuant to Rule 424(b) as part of a registration statement
relating to an offering, other than registration statements relying
on Rule 430B or other than prospectuses filed in reliance on Rule
430A, shall be deemed to be part of and included in the
registration statement as of the date it is first used after
effectiveness. Provided, however, that no
statement made in a registration statement or prospectus that is
part of the registration statement or made in a document
incorporated or deemed incorporated by reference into the
registration statement or prospectus that is part of the
registration statement will, as to a purchaser with a time of
contract of sale prior to such first use, supersede or modify any
statement that was made in the registration statement or prospectus
that was part of the registration statement or made in any such
document immediately prior to such date of first use.
5)
That, for the purpose of determining liability of the registrant
under the Securities Act to any purchaser in the initial
distribution of the securities, the undersigned registrant
undertakes that in a primary offering of securities of the
undersigned registrant pursuant to this registration statement,
regardless of the underwriting method used to sell the securities
to the purchaser, if the securities are offered or sold to such
purchaser by means of any of the following communications, the
undersigned registrant will be a seller to the purchaser and will
be considered to offer or sell such securities to such
purchaser:
i.
Any preliminary prospectus or prospectus of the undersigned
registrant relating to the offering required to be filed pursuant
to Rule 424;
ii.
Any free writing prospectus relating to the offering prepared by or
on behalf of the undersigned registrant or used or referred to by
the undersigned registrant;
iii.
The portion of any other free writing prospectus relating to the
offering containing material information about the undersigned
registrant or its securities provided by or on behalf of an
undersigned registrant; and
iv.
Any other communication that is an offer in the offering made by
the undersigned registrant to the purchaser.
6)
That, for purposes of determining any liability under the
Securities Act, each filing of the registrant’s annual report
pursuant to section 13(a) or section 15(d) of the Exchange Act
(and, where applicable, each filing of an employee benefit plan’s
annual report pursuant to section 15(d) of the Exchange Act) that
is incorporated by reference in the registration statement shall be
deemed to be a new registration statement relating to the
securities offered therein, and the offering of such securities at
that time shall be deemed to be the initial bona fide offering
thereof.
7) To
file an application for the purpose of determining the eligibility
of the trustee to act under subsection (a) of Section 310
of the Trust Indenture Act in accordance with the rules and
regulations prescribed by the Commission under
Section 305(b)(2) of the Trust Indenture Act.
Insofar
as indemnification for liabilities arising under the Securities Act
may be permitted to directors, officers and controlling persons of
the registrant pursuant to the foregoing provisions, or otherwise,
the registrant has been advised that in the opinion of the
Securities and Exchange Commission such indemnification is against
public policy as expressed in the Act and is, therefore,
unenforceable. In the event that a claim for indemnification
against such liabilities (other than the payment by the registrant
of expenses incurred or paid by a director, officer or controlling
person of the registrant in the successful defense of any action,
suit or proceeding) is asserted by such director, officer or
controlling person in connection with the securities being
registered, the registrant will, unless in the opinion of its
counsel the matter has been settled by controlling precedent,
submit to a court of appropriate jurisdiction the question whether
such indemnification by it is against public policy as expressed in
the Act and will be governed by the final adjudication of such
issue.
SIGNATURES
Pursuant
to the requirements of the Securities Act of 1933, the registrant
certifies that it has reasonable grounds to believe that it meets
all of the requirements for filing on Form S-3 and has duly caused
this registration statement to be signed on its behalf by the
undersigned thereunto duly authorized in the City of Newark, State
of New Jersey, on February 24, 2021.
|
RAFAEL
HOLDINGS, INC. |
|
|
|
|
By: |
/s/
Howard
Jonas |
|
|
Howard
Jonas |
|
|
Chairman
of the Board of Directors and
Chief Executive Officer |
POWER
OF ATTORNEY
KNOW
ALL PERSONS BY THESE PRESENTS, that each person whose signature
appears below constitutes and appoints Joyce Mason as his true and
lawful attorneys-in-fact and agents, with full powers of
substitution and resubstitution, for him and in his name, place and
stead, in any and all capacities, to sign any and all amendments to
this registration statement (including post-effective amendments
and any related registration statements filed pursuant to Rule 462
and otherwise), and to file the same with all exhibits thereto, and
other documents in connection therewith, with the Securities and
Exchange Commission, granting unto said attorneys-in-fact and
agents and full power and authority to do and perform each and
every act and thing requisite and necessary to be done in
connection therewith, as fully for all intents and purposes as he
might or could do in person, hereby ratifying and confirming that
said attorney-in-fact and agent, or any substitute or resubstitute,
may lawfully do or cause to be done by virtue hereof.
Pursuant
to the requirements of the Securities Act of 1933, as amended, this
registration statement has been signed by the following persons in
the capacities indicated and as of February 24, 2021.
Signature |
|
Titles |
|
|
|
|
|
/s/
Howard S. Jonas |
|
Chairman
of the Board and Chief Executive Officer |
|
Howard
S. Jonas |
|
(Principal
Executive Officer) |
|
|
|
|
|
/s/
David Polinsky |
|
Chief
Financial Officer |
|
David
Polinsky |
|
(Principal
Financial Officer and Principal Accounting Officer) |
|
|
|
|
|
/s/
Stephen Greenberg |
|
Director |
|
Stephen
Greenberg |
|
|
|
|
|
|
|
/s/
Rachel Jonas |
|
Director |
|
Rachel Jonas |
|
|
|
|
|
|
|
/s/
Boris C. Pasche
|
|
Director |
|
Dr.
Boris C. Pasche |
|
|
|
|
|
|
|
/s/
Michael J. Weiss |
|
Director |
|
Dr.
Michael J. Weiss |
|
|
|
EXHIBIT
INDEX
|
(1) |
Incorporated
by reference to Form 10-12G/A, filed March 26, 2018. |
|
(2) |
Incorporated
by reference to Form 8-K, filed September 26, 2019. |
II-5